MAP2K7 and Patent ductus arteriosus: In conclusion, the combination of MEK inhibitor GDC-0623 and agonist anti-CD40 Ab is a highly potent regimen for the treatment of tumors, especially for cancers such as PDA that are driven by mutated KRAS and heavily infiltrated by myeloid cells.